Overview

KN026 in Combination With Chemotherapy in the Second Line Treatment of HER-2 Positive Advanced or Metastatic Gastric Cancer

Status:
Recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together. Randomized stage is designed to evaluate the OS and PFS in patients receiving KN026 and chemotherapy compared to patients receiving placebo and chemotherapy.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Shanghai JMT-Bio Inc.

Treatments:

Docetaxel
Irinotecan
Paclitaxel